Windlas Biotech Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uz0nsjuo80z19y84aknh1v4v.pdf

Key Takeaways


CDMO: Flat Quarter, Unchanged Story

Hitesh Windlass: "My sense is that strategically and structurally, there is no change. We expect the CDMO vertical also on the back of our new product launches and patent expiries like you mentioned, to come back into growth phase."

Trade Generics: The Growth Engine

Hitesh Windlass: "Our idea and philosophy is that we will give authentic, affordable and accessible products in this trade generics vertical is what we are leading with."

Margins: Mix Help, R&D Drag

Hitesh Windlass: "In a B2B environment, if you get desperate to fill capacity, you very quickly lose margin. And so, our focus has been to not go after the largest opportunities, not go after the smallest and sort of target this medium space, where we are doing something complex, and we are able to offer a sustainable partnership to our customer."

Regulatory & Facility Updates


Strategic Direction

Komal Gupta: "We don't recall losing any customer over the period of the life of the customer."

Guidance & Commitments

CommitmentSpecificsTimeline
CDMO revenue doublingDouble CDMO business from FY22 baseOver five years (by FY27)
Trade generics revenue share15% to 20% of overall revenueThree to four years
Trade generics scaleTriple the business from its baseOver five years (by FY27)
Exports scaleQuadruple the business from its baseOver five years (by FY27)
Injectable facility first commercial batchFirst batch outBy March FY23 (end of FY23)
R&D spend targetAround 2% of revenueLong-term, no specific year
CDMO growth resumptionGrowth to return on back of new launches and Sitagliptin patent expiryQ2 FY23 onward

Key Metrics

MetricQ1 FY23
Consolidated revenue₹119.9 crores, up 8.1% YoY
Consolidated EBITDA₹13.8 crores, up 11.4% YoY
Consolidated PAT₹9.8 crores, up 46.6% YoY
EBITDA margin11.5%, up from 11.2% YoY; expansion limited by accelerated R&D costs
CDMO vertical revenue₹94.8 crores, largely flattish YoY; contributed ~79% of consolidated revenue
Trade generics vertical revenue₹21.4 crores, up 73.2% YoY; contributed ~18% of consolidated revenue
Trade generics margin premium4% to 5% higher than CDMO business margin
CDMO long-term growth targetDouble CDMO business over five years
Trade generics long-term growth targetTriple trade generics business over five years
Exports long-term growth targetQuadruple exports business over five years
Complex generics share of output75% of output this quarter
Capacity utilization~40%
New CDMO customers added in Q1more than 75 new customers added; sales to ramp over time
R&D spend target~2% of revenue long-term, up from ~1% in FY20-21
Cash reserves on balance sheet~₹200 crores